MilliporeSigma, the life sciences arm of Merck KGaA, has opened a new viral-vector manufacturing facility in Carlsbad, California, to expand its CDMO footprint.

This new $110-million, 140,000-square-foot facility will more than double existing capacity to support large-scale commercial and industrial manufacturing for viral gene therapies.

This is the company’s second Carlsbad, California-based facility for viral vector-based therapies. Between the two facilities, there are 30 cleanroom suites to support manufacturing from small- to large-scale clinical and commercial production. The new facility uses suspension technology and enables suspension production of viral vectors up to 1,000-liter scale.

Source: MilliporeSigma